Spontaneous bacterial peritonitis: A therapeutic update

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 2, 2006, Pages 249-260

  Strauss, Edna ^a   Caly, Wanda R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antibiotic therapy; Ascites; Bacterial infection; Chronic liver disease; Hepatic cirrhosis; Prophylaxis; Spontaneous bacterial peritonitis

Indexed keywords

ALBUMIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CEFADROXIL; CEFONICID; CEFOTAXIME; CEFTIZOXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; ESTERASE; METRONIDAZOLE; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; PLACEBO; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

ABDOMINAL PAIN; AEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ASCITES; BACTERIAL GROWTH; BACTERIAL PERITONITIS; BACTERIAL TRANSLOCATION; BACTERIUM CULTURE; BACTERIUM ISOLATION; BODY FLUID; CELL COUNT; CLINICAL TRIAL; DIAGNOSTIC VALUE; DIARRHEA; DISEASE COURSE; DRUG ABSORPTION; DRUG CHOICE; DRUG COST; DRUG DIFFUSION; DRUG EFFICACY; DRUG PENETRATION; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL MOTILITY DISORDER; GENUS; GRAM NEGATIVE BACTERIUM; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; ILEUS; INTESTINE BLOOD FLOW; INTESTINE FLORA; KIDNEY DISEASE; LABORATORY TEST; LACTOBACILLUS; LIVER CIRRHOSIS; MESENTERY LYMPH NODE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA AND VOMITING; NONHUMAN; PARACENTESIS; PATHOGENESIS; PERITONEAL DISEASE; POLYMORPHONUCLEAR CELL; PREVALENCE; PROBABILITY; PROPHYLAXIS; RAT; RECURRENCE RISK; REVIEW; STREPTOCOCCUS; SUPERINFECTION; SURVIVAL RATE; SYMPTOM; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; HUMANS; PERITONITIS;

EID: 33646165056     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.2.249     Document Type: Review

References (94)

1. Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J. Hepatol. 18, 353-358 (1993).
2. Grange JD, Amiot X. Antibiotic prophylaxis of ascitic fluid infection. Gastroenterol. Clin. Biol. 22, 301-304 (1998).
3. Rimola A, Garcia-Tsao G, Navasa M et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J. Hepatol. 32, 142-153 (2000).
4. Fernanadez J, Bauer TM, Navasa M, Rodés J. Diagnosis, treatment and prevention of spontaneous bacterial peritonitis. Ballieres Clin. Gastroenterol. 14, 975-990 (2000).
5. Evans LT, Kim WR, Poterucha JJ, Kamath PS. Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology 37, 897-890 (2003).
6. Titó L, Rimola A, Ginés P. Llach J, Arroyo V, Rodés J. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 8, 27-31 (1988).
7. Kerr DNS, Pearson DT, Read AE. Infection of ascitic fluid in patients with hepatic cirrhosis. Gut 4, 394-398 (1963).
8. Conn HO. Spontaneous peritonitis and bacteremia in Laennec's cirrhosis caused by enteric organisms. A relatively common but rarely recognized syndrome. Ann. Intern. Med. 60, 568-580 (1964).
9. Toledo C, Salmerón JM, Rimola A et al. Spontaneous bacterial peritonitis in cirrosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology 17, 251-257 (1993).
10. Rimola A, Bory F, Pianas R, Xaubert A, Bruguera M, Rodés J. Infecciones bacterianas agudas em la cirrosis hepática. Gastroenterol. Hepatol. 9, 453-459 (1981).
11. Runyon BA, Hoefs JC. Ascitic fluid analysis in the differentiation of spontaneous bacterial peritonitis from gastrointestinal tract perforation into ascitic fluid. Hepatology 4, 447-450 (1984).
12. Fernandez J. Navasa M, Gomez J et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 35, 140-148 (2002).
13. Singh N, Wagener MM, Gayowski T. Changing epidemiology and predictors of mortality in patients with spontaneous bacterial peritonitis at a liver transplantation unit. Clin. Microbiol. Infect. 9, 531-537 (2003).
14. Garcia-Tsao G. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract. Res. Clin. Gastroenterol. 18, 353-372 (2004).
15. Garcia-Tsao G. Milestones in liver disease. Spontaneous bacterial peritonitis: a historical perspective. J. Hepatol. 41, 522-527 (2004).
16. Garcia-Tsao G, Lee FY, Barden GE, Cartun R, West AB. Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology 108, 1835-1841 (1995).
17. Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 120, 726-748 (2001).
18. Guarrier C, Soriano G. Spontaneous bacterial peritonitis. Semin. Liver Dis. 17, 203-217 (1997).
19. Llovet JM, Bartoli R, Planas R et al. Selective intestinal decontamination with norfloxacin reduces bacterial translocation in ascitic cirrhotic rats exposed to hemorrhagic shock. Hepatology 23, 781-787 (1996).
20. Guarner C, Runyon BA, Young S, Heck M, Sheikl MY. Effect of long term trimethroprim-sulfamethoxazole prophylaxis on ascites formation, bacterial translocation, spontaneous bacterial peritonitis and survival in cirrhotic rats. Dig. Dis. Sci. 44, 1957-1962 (1999).
21. Cirera I, Bauer TM, Navasa M et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J. Hepatol. 34(1), 150-155 (2001).
22. Pérez-Paramo M, Muñoz J, Albillos A, Freile I, Portero F, Santos M. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology 3l, 43-48 (2000).
23. Guarner C, Runyon BA, Young S, Heck M, Sheih MY. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J. Hepatol. 26, 1372-1378 (1997).
24. Chiva M, Guarner C, Peralta. C et al. Intestinal mucosal oxidative damage and bacterial translocation in cirrhotic rats. Eur. J. Gastroenterol. Hepatol. 15, 145-150 (2003).
25. Navasa M, Rimola A, Rodés J. Bacterial infections in liver disease. Semin. Liver Dis. 17(4), 323-333 (1997).
26. Runyon BA. Patients with deficient ascitic fluid opsonic activity are predisposed to spontaneous bacterial peritonitis. Hepatology 8, 632-635 (1988).
27. Llach J, Rimola A, Navasa M et al. Incidence and predictive of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration. Hepatology 16, 724-727 (1992).
28. Runyon BA. Low-protein concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology 91, 1343-1346 (1986).
29. Guarner C, Sola R, Soriano G et al. Risk of a first community-acquired spontaneous bacterial peritonitis in cirrhotics with low ascitic fluid protein levels. Gastroenterology 117, 414-419 (1999).
30. Albillos A, de las Heras A, Alvares-Mon M. Serum lipopolysaccharide-binding protein prediction of severe bacterial infection. Lancet 363, 1608-1610 (2004).
31. Frances R, Munoz C, Zapater P et al. Bacterial DNA activates cell-mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites. Gut 53, 860-864 (2004).
32. Garcia-Tsao G. Portal hypertension. Curr. Opin. Gastroenterol. 212, 313-322 (2005).
33. Rimola A, Garcia-Tsao G, Navasa M et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J. Hepatol. 32, 142-153 (2000).
34. Runyon BA. Management of adults patients with ascites due to cirrhosis. Hepatology 39(3), 1-16 (2004).
35. Deitch EA, Morrizon J, Berg RD. Effect of hemorrhagic schock on bacterial translocation, intestinal morphology and intestinal permeability in conventional and antibiotic-decontaminated rats. Crit. Care Med. 18, 529-536 (1990).
36. Wong F, Bernardi M, Balk R et al. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut 54, 718-725 (2005).
37. Brolin RE. Fulminant onset of spontaneous bacterial peritonitis. Dig. Dis. Sci. 27, 364-366 (1982).
38. Runyon BA. Ascites and spontaneous bacterial peritonitis. In: Gastrointestinal and Liver Disease (Seventh Edition). Feldman M, Friedman LS, Sleisenger MH (Eds), Saunders, PA, USA, 1517-1542 (2002).
39. Runyon BA, Hoefs JC. Culture-negative neutrocytic ascites: a variant of spontaneous bacterial peritonitis. Hepatology 4, 1209-1211 (1984).
40. Garcia-Tsao G. Spontaneous bacterial peritonitis. Hepatol. Rev. 2, 108-112 (2004).
41. Castellote J, López C, Gornals J et al. Rapid diagnosis of spontaneous bacterial peritonitis by use of reagent strips. Hepatology 37, 893-896 (2003).
42. Sapey T, Mandler MH, Kabissa D et al. Apport diagnostique des bandelettes urinaires (Nephur-Test et MultistixSG) dans l'infection spontanée du liquide d'ascite chez le cirrhotique (résumé). Gastroenterol. Clin. Biol. 27, CO30 (2003).
43. Vanbiervliet G, Rakotoarisoa C, Filippi J et al. Diagnostic accuracy of a rapid urine- screening test (Multistix 8 SG) in cirrhotic patients with spontaneous bacterial peritonitis. Eur. J. Gastroenterol. Hepatol. 14, 1257-1260 (2002).
44. Sapey T, Kabissa D, Fort E, Laurin C, Mendler MH. Instant diagnosis of spontaneous bacterial peritonitis using leukocyte esterase reagent strips: Nephur-Test vs. MultistixSG. Liver Int. 25 (3), 343-348 (2005).
45. Strauss E, Caly WR. Spontaneous bacterial zperitonitis. Rev Soc. Bras. Med. Trop. 36(5), 711-717 (2003).
46. Jeffries MA, Stern MA, Guamaratnum NT, Fontana RJ. Unsuspected infection is infrequent in asymptomatic out patients with refractory ascites undergoing therapeutic paracentesis. Am. J. Gastroenterol. 94, 2972-2976 (1999).
47. Romney R, Mathurin P, Ganne-Carrie N et al. Usefulness of routine analysis of ascitic fluid at the time of therapeutic paracentesis in asymptomatic outpatients. Results of a multicenter prospective study. Gastroenterol. Clin. Biol. 29(3), 275-279 (2005).
48. Cholongitas E, Papatheodoridis GV, Lahanas A, Xanthaki A, Kontou-Kastellanou C, Archimandritis AJ. Increasing frequency of Gram-positive bacteria in spontaneous bacterial peritonitis. Liver Int. 25, 57-61 (2005).
49. Campillo B, Richardet J-P, Kheo T, Dupeyron C. Nosocomial spontaneous bacterial peritonitis and bacteremia in cirrhotic patients: impact of isolate type on prognosis and characteristics of infection. Clin. Infect. Dis. 35, 1-10 (2002).
50. Dupeyron C, Campillo B, Mangeney N, Richardet JP, Leluan G. Changes in nature and antibiotic resistance of bacteria causing peritonitis in cirrhotic patients over a 20 year period. J. Clin. Pathol. 51(8), 614-616 (1998).
51. Paterson DL. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin. Infect. Dis. 38(4), S341-S345 (2004).
52. Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureusin hospitalized patients. Emerg. Infect. Dis. 9(11), 1415-1422 (2003).
53. MacDougall C, Harpe SE, Powell JP, Johnson CK, Edmond MB, Polk RE. Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use. Emerg. Infect. Dis. 11(8), 1197-1204 (2005).
54. Campillo B, Dupeyron C, Richardet JP, Mangeney N, Leluan G. Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of longterm administration of norfloxatin. Clin. Infect, Dis. 26(5), 1066-1070 (1998).
55. Campillo B, Dupeyron C, Richardet JR Epidemiology of hospital-acquired infections in cirrhotic patients: effect of carriage of methicillin-resistant Staphylococcus aureus and influence of previous antibiotic therapy and norfloxacin prophylaxis. Epidemiol. Infect. 127(3), 443-450 (2001).
56. Desai D, Desai N, Nightingale P, Elliott T, Neuberger J. Carriage of methicillin-resistant Staphyllococcus aureus is associated with an increased risk of infection after liver transplantation. Liver Traspl. 9(7), 754-759 (2003).
57. Rimola A, Salmerón JM, Clemente G et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study. Hepatology 21, 674-679 (1995).
58. Navasa M, Follo A, Llovet JM et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology 111, 1011-1017 (1996).
59. Ricart E, Soriano G, Novella MT et al. Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients. J. Hepatol. 32, 596-602 (2000).
60. Strauss E, Ribeiro MFGS. Bacterial infections associated with hepatic encephalopathy: prevalence and outcome. Ann. Hepatol. 2(1), 41-45 (2003).
61. Arroyo V, Jimenez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J. Hepatol. 32, 157-160 (2000).
62. Such J, Hilebrand DJ, Guarner C et al. Nitric oxide in ascitic fluid is an independent predictor of the development of renal impairment in patients with cirrhosis and spontaneous bacterial peritonitis. Eer. J. Gastroenterol. 16, 571-577 (2004).
63. Lopez-Talavera JG, Cadelina G, Olchowski J, Merril W, Groszmann R. Thalidomide inhibits tumor necrosis alpha, decreases nitric oxide synthesis and ameliorates the hyperdynamic circulatory syndrome in portal hypertensive rats. Hepatology 23, 1616-1621 (1996).
64. Wiest S, Das G, Cadelina G, Miltien S, Garcia-Tsao G, Groszmann R. Bacterial translocation to limph nodes of cirrhotic rats stimulates e NOS-derived NO production and impairs mesenteric vascular contractility. J. Clin. Invest. 104, 1223-1233 (1999).
65. Ruiz-del-Arbol L, Urmam J, Gonzalez M et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 38, 1210-1218 (2003).
66. Strauss S, Caly WR, Ribeiro MFG et al. Spontaneous bacterial peritonitis-predictive factors of non-response to I.V. cephalosporin (3rd generation) Hepatology 34(4), 540A (2001).
67. Pinzello G, Simonetti R, Camma C et al. Spontaneous bacterial peritonitis: an update. Gastroenterol. Int. 6, 54-60 (1993).
68. Grangé JD. Ascite-comment traiter une ascite? Gastroenterol. Clin. Biol. 28, 8278-8286 (2004).
69. Felisart J, Rimola A, Arroyo V et al. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatolgy 5, 457-462 (1985).
70. Runyon BA, Akriviadis EA, Sattler FR et al. Ascitic fluid and serum cefotaxime and desacetyl cefotaxime levels in patients treated for peritonial peritonitis. Dig. Dis. Sci. 36(12), 1782-1786 (1991).
71. Runyon BA, McHutchison JC, Antillon MR, Akriviadis EA, Montano AA. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. Gastroenterology 100, 1737-1742 (1991).
72. Grange JD, Amiot X, Grange V et al. Amoxicillin-clavulanic acid therapy of spontaneous bacterial peritonitis: a prospective study of twenty-seven cases in cirrhotic patients. Hepatology 11, 360-364 (1990).
73. Gomez-Jimenez J, Ribera E, Gasser I et al. Randomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous bacterial peritonitis in cirrhotic patients. Antimicrob. Agents Chemother. 37(8), 1587-1592 (1993).
74. Mercader J, Gomez J, Ruiz J, Garre MC, Valdes M. Use of ceftriaxone in the treatment of bacterial infections in cirrhotic patients. Chemotherapy 35(Suppl. 2), 23-26 (1989).
75. Rimola A, Titó L, Llach J et al. Efficacy of ceftizoxime in the treatment of severe bacterial infections in patients with cirrhosis. Drug Invest. 4 (Suppl. 1), 35-37 (1992).
76. Silvain C, Breux JP, Grollier G et al. Les septicemias et les infections du liquide d'ascite du cirrhotique peuvent-elles étre traitées exclusivement par voie orale? Gastroenterol. Clin. Biol. 13, 335-339 (1989).
77. Terg R, Cobas S, Fassio E et al. Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter, randomized study. J. Hepatol. 33, 564-569 (2000).
78. Follo A, Llovet JM, Navasa M et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 20, 1495-1501 (1994).
79. Navasa M, Folio A, Filelia X et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis: relationship with the development of renal impairment and mortality. Hepatology 20, 819-824 (1998).
80. Ginés P, Guevara M, de las Heras D, Arroyo V. Review article: albumin for circulatory support in patients with cirrhosis. Aliment. Pharmacol. Ther. 16(Suppl. 5), 24-31 (2002).
81. Sort P, Navasa M, Arroyo V et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N. Engl. J. Med. 341, 403-409 (1999).
82. Navasa M, Rodes J. Bacterial infections in cirrhosis. Liver Int. 24, 277-280 (2004).
83. Shalit I. Immunological aspects of new quinolonas. Eur. J. Microbiol. Infect. Dis 10, 262-266 (1991).
84. Rimola A, Bory F, Terés J, Pérez-Ayuso Rm, Arooyo V, Rodés J, Oral non-absorbable antibiotics prevent infection in cirrhosis with gastrointestinal hemorrhage. Hapatology 5, 463-467 (1985).
85. Soriano G, Guarner C, Tomas A et al. Norfloxacine prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology 103, 1267-1272 (1992).
86. Bernard B, Grange JD, Khac EN, Amiot X Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 29, 1655-1661 (1999).
87. Novella M, Sola R, Soriano G et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology 25, 532-536 (1997).
88. Grange JD, Roulot D, Pelletier G et al. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites - a double blind randomized trial. J. Hepatol. 29, 430-436 (1998).
89. Soriano G, Guarner C, Teixido M et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 100(2), 477-481 (1991).
90. Gines, P, Rimola A, Planas R, Vergas V, Marco F. Almeida M. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a doublé-blind, placebo-controlled trial. Hepatology 12, 716-724 (1990).
91. Bernard B, Grange JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with ascites: a meta-analysis. Digestion 59, 54-57 (1998).
92. Younossi ZM, McHutchinson JG, Gamiats TG. An economic analysis of norfloxacin prophylaxis against spontaneous bacterial peritonitis. J. Hepatol. 27, 295-298 (1997).
93. Pardo A, Bartoli R, Lorenzo Zuniga V et al. Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis. Hepatology 3l, 858-863 (2000).
94. Bauer TM, Fernanadez J, Navasa M et al. Failure of Lactobacillus spp. to prevent bacterial translocation on a rat model of experimantal cirrhosis. J. Hepatol. 36, 501-506 (2002).